TITLE

Effects of Naftidrofuryl in Patients With Intermittent Claudication

AUTHOR(S)
Karnik, Ronald; Valentin, Andreas; Stöllberger, Claudia; Slany, Jöry
PUB. DATE
March 1988
SOURCE
Angiology;Mar1988 Part 1, Vol. 39 Issue 3, p234
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In a randomized, double-blind, placebo-controlled study in patients with peripheral arterial occlusive disease stage lib of Fontaine's classification, the efficacy of naftidrofuryl, a vasoactive substance, was investigated. Forty patients – 31 men and 9 women with an average age of 62.98 ± 10.65 years – were admitted to the study. All had a history of claudication for at least six months. The duration of the trial was eighteen weeks. After a washout period of two weeks the patients received either two times 400 mg naftidrofuryl or two identical placebo tablets daily for eight weeks. Subsequently a crossover from verum to placebo and vice versa was carried out and the alternative medication was administered for another eight weeks. Clinical results were evaluated by measuring painfree and maximal walking distance by treadmill test at a speed of 3.2 km/h and an inclination of 12°. Systolic ankle pressure and brachial pressure were measured by Doppler ultrasound, and ankle/arm pressure ratio was calculated. Treadmill test, Doppler ultrasound examination, and laboratory data analysis were performed at the beginning of every study period, every four weeks during and at the end of the study. Results. The patients in both groups showed an initial homogeneity of age, risk factors, concomitant diseases, walking distance, and Doppler indices. After eight weeks naftidrofuryl resulted in a statistically significant increase in painfree (p<0.02) and maximal walking distance (p < 0.05). The placebo-treated group showed only a slight, statistically nonsignificant increase in both painfree and maximal walking distance. After crossover the administration of naftidrofuryl produced a further increase in painfree walking distance (p<0.05), whereas in the group crossed over to placebo, both painfree and maximal walking distance remained unchanged. Systolic ankle blood pressure and ankle/arm pressure ratio showed no significant alterations in both groups within the study period. The authors conclude that naftidrofuryl is an efficient vasoactive drug, which significantly improves walking distance in patients with peripheral arterial occlusive disease stage IIb.
ACCESSION #
16344760

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics